Researchers at UTHealth Houston reported preclinical results in Science Translational Medicine showing that monoclonal antibodies inhibiting matrix metalloproteinase-9 (MMP-9) can slow and even reverse diabetic peripheral neuropathy in mouse models of both type 1 and type 2 diabetes. The work focuses on neuroinflammation and microvascular dysfunction mechanisms tied to MMP-9. The study’s framing matters for drug development because diabetic peripheral neuropathy is widely treated symptomatically, and the authors positioned MMP-9 as both sufficient and required for neuropathy pathogenesis in their models. The approach aims to become a disease-modifying therapy rather than a pain-control strategy. For translational planning, the key next step is moving from the animal data package to candidates’ safety and target engagement characteristics in humans, particularly for chronic use in a systemic metabolic disease. The publication also underscores the broader immuno-neurovascular angle increasingly pursued in neuropathy programs as companies look for upstream targets that may affect progression.